Skip to main
SGHT

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc is positioned for solid revenue growth, driven by accelerated market share gains in minimally invasive glaucoma surgery (MIGS) and quicker adoption of its TearCare product. The company’s Surgical Glaucoma segment is expected to sustain growth in line with the overall MIGS market, reinforcing its potential for future success. Additionally, improved earnings per share (EPS) projections reflect a positive trend towards profitability, with estimates for 2025 and 2026 indicating a decrease in losses from previous forecasts.

Bears say

Sight Sciences Inc. has reiterated its 2025 revenue guidance of $72-76 million, indicating persistent challenges, particularly with expected mid-single digit percentage declines in Surgical Glaucoma revenue for the third quarter of 2025. The company faces significant risks, including intensified competition in minimally invasive glaucoma surgery (MIGS) and slow advancements in securing insurance coverage for its TearCare System, along with ongoing concerns about high cash burn rates. Additionally, while management has lowered its adjusted operating expense guidance for 2025 from $101-105 million to $95-99 million, the anticipated savings from workforce reductions highlight the need to improve financial efficiency amidst these challenges.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.